Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Recurso digital |
| Language: | English |
| Published: |
Zenodo
2025
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.15570010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866902294810853376 |
|---|---|
| author | Seyyar, Mustafa Can Şancı, Pervin Çabuk, Devrim |
| author_facet | Seyyar, Mustafa Can Şancı, Pervin Çabuk, Devrim |
| contents | <p>We report a case of a 49-year-old female with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd) after progression on multiple prior lines of therapy. Following the third cycle, she developed dyspnea and was admitted to the coronary intensive care unit with heart failure and pulmonary edema. Echocardiography revealed an ejection fraction (EF) of 10-15%. Imaging demonstrated unilateral pleural effusion and bilateral pulmonary infiltrates. Clinical findings were attributed to T-DXd-induced heart failure, bicytopenia, and pneumonitis. The patient responded well to corticosteroid therapy, showing resolution of pulmonary findings and an improved EF (30-35%) over two weeks. This case highlights the importance of monitoring and managing cardiopulmonary adverse events in patients receiving T-DXd.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15570010 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Management of Trastuzumab Deruxtecan-Induced Heart Failure and Pneumonitis in a Patient with HER2-Positive Metastatic Breast Cancer Seyyar, Mustafa Can Şancı, Pervin Çabuk, Devrim Receptor, ErbB-2 Trastuzumab Deruxtecan Heart Failure Pneumonitis Steroids <p>We report a case of a 49-year-old female with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd) after progression on multiple prior lines of therapy. Following the third cycle, she developed dyspnea and was admitted to the coronary intensive care unit with heart failure and pulmonary edema. Echocardiography revealed an ejection fraction (EF) of 10-15%. Imaging demonstrated unilateral pleural effusion and bilateral pulmonary infiltrates. Clinical findings were attributed to T-DXd-induced heart failure, bicytopenia, and pneumonitis. The patient responded well to corticosteroid therapy, showing resolution of pulmonary findings and an improved EF (30-35%) over two weeks. This case highlights the importance of monitoring and managing cardiopulmonary adverse events in patients receiving T-DXd.</p> |
| title | Management of Trastuzumab Deruxtecan-Induced Heart Failure and Pneumonitis in a Patient with HER2-Positive Metastatic Breast Cancer |
| topic | Receptor, ErbB-2 Trastuzumab Deruxtecan Heart Failure Pneumonitis Steroids |
| url | https://doi.org/10.5281/zenodo.15570010 |